ArticleFrontiers in immunology2025
A comparative study of large-vessel and small-vessel primary angiitis of the central nervous system: insights from a Chinese single-center retrospective cohort.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Overview of Primary Angiitis of the Central Nervous System: Current Insights.Archives of internal medicine research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary angiitis of the central nervous system (PACNS) is a rare immune-mediated vasculitis with distinct subtypes (large/medium-vessel [LV-PACNS] and small-vessel [SV-PACNS]). This study aims to provide evidence-based data from the Chinese population for improving the subtype-specific management system of PACNS. Methods: This retrospective single-center study enrolled 47 PACNS patients (29 with SV-PACNS, 18 with LV-PACNS) who met the 1988 Calabrese and Mallek diagnostic criteria, with a follow-up duration ≥1 year. Clinical phenotypes, imaging characteristics, treatment, prognosis, and factors influencing prognosis were retrospectively analyzed in both groups. Results: Compared with LV-PACNS, SV-PACNS had more severe initial neurological impairment (baseline modified Rankin Scale mRS score: 3 vs. 2, p=0.043) and a longer median time from onset to treatment initiation (154 days vs. 58.5 days, p=0.013). In terms of clinical features, LV-PACNS had a higher incidence of cerebrovascular events (88.9% vs. 58.2%, p=0.027) and limb weakness/sensory abnormalities (83.3% vs. 34.5%, p=0.001), while SV-PACNS had a higher incidence of tumor-like lesions (41.4% vs. 5.6%, p=0.008). Imaging features showed that 100% of LV-PACNS patients had cerebrovascular stenosis, of which 94.4% exhibited circumferential vascular wall enhancement; and compared with SV-PACNS, they had a higher incidence of ischemic infarction (66.7% vs 20.7%, p=0.002). Multivariate analysis confirmed that time from onset to treatment was an independent risk factor for poor 1-year prognosis (mRS score > 2) in both subtypes (SV-PACNS: OR = 1.012, p=0.021; LV-PACNS: OR = 1.048, p=0.040). Conclusions: This study identified the core clinical and neuroimaging differences between LV-PACNS and SV-PACNS, and pointed out that treatment delay are the main issues affecting prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.